CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES
Mohammadi H, Tolpin A, Figura N, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Vogelbaum M, Robinson T, Yu M. CMET-17. RENAL CELL CARCINOMA BRAIN METASTASES TREATED WITH STEREOTACTIC RADIATION THERAPY AND NIVOLUMAB DOES NOT ALTER LESIONAL OR CLINICAL OUTCOMES. Neuro-Oncology 2019, 21: vi54-vi55. PMCID: PMC6847278, DOI: 10.1093/neuonc/noz175.218.Peer-Reviewed Original ResearchStereotactic radiotherapyMedian timeRenal cell carcinoma brain metastasesDistant brain failureStage IV RCCMedian overall survivalOptimal treatment sequenceCox regression modelStereotactic radiation therapyWarrants further investigationDistant brainEligible lesionsNivolumab administrationBrain metastasesConsecutive patientsOverall survivalClinical outcomesBrain failureKaplan-MeierRetrospective databaseHemorrhagic lesionsNivolumabRadiation therapyPatient basisPatientsOutcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab
Mohammadi H, Tolpin A, Peacock J, Oliver D, Sim A, Palm R, Ahmed K, Liu J, Tran N, Etame A, Robinson T, Yu M. Outcomes in Brain Metastatic Renal Cell Carcinoma Treated with Stereotactic Radiation Therapy and Nivolumab. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e82. DOI: 10.1016/j.ijrobp.2019.06.2349.Peer-Reviewed Original Research